StroMedix Receives $2,000,000 New Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Canal Park Cambridge, MA 02141
  • Company Description
    Stromedix is a clinical-stage biotechnology company committed to developing novel drugs to treat fibrotic organ failure. Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. The company plans to build its pipeline through both internal drug discovery and in-licensing.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor